Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)
First Approved Therapy in the United States for Patients with TIO Who Cannot Undergo Surgical Removal of TumorsTIO is Second […]